スマート吸入器技術市場：製品タイプ、適応症、流通チャネル、地域別、2026～2032年

スマート吸入器技術市場の評価-2026～2032年

COPDや喘息の有病率が高い高齢者の増加が、スマート吸入器の需要を牽引しています。高齢者は重篤な呼吸器疾患や合併症を起こしやすいため、先進的吸入器技術が不可欠となります。したがって、高齢者の増加は、市場規模の成長を急増させ、2024年には138億1,000万米ドルを超え、2032年には577億米ドルの評価額に達します。

COVID-19症例の増加とそれに伴う呼吸器合併症は、効果的な呼吸管理ツールの必要性を高めています。スマート吸入器は、呼吸器疾患を管理し、入院リスクを減らすために重要な、強化されたモニタリングとアドヒアランス機能を記載しています。したがって、COVID-19パンデミックの増加と効果的な呼吸器管理ツールの成長により、市場は2026～2032年までCAGR 19.6％で成長します。

スマート吸入器技術市場定義/概要

スマート吸入器技術には、喘息やCOPDなどの呼吸器疾患を管理するために使用される従来型吸入器デバイスに、デジタルセンサと接続機能を統合することが含まれます。これらの先進的吸入器は薬の使用状況を追跡し、患者とヘルスケアプロバイダの両方に重要なデータを記載しています。投与量をモニターするセンサを備えたスマート吸入器は、データをモバイルアプリやクラウドプラットフォームにワイヤレスで送信し、そこで分析・表示されます。

患者にとって、スマート吸入器はリアルタイムのフィードバックを提供し、服薬スケジュールの遵守、吸入技術の向上、タイムリーな使用のためのリマインダーの受信を支援します。これは、より良い疾病管理、喘息発作やCOPD増悪の減少、生活の質の向上につながります。

ヘルスケアプロバイダは、スマート吸入器によって生成されるデータから恩恵を受け、遠隔で服薬アドヒアランスをモニタリングし、使用パターンを特定し、治療計画を調整することができます。このデータ駆動型アプローチにより、個別化されたプロアクティブケアが可能になり、その結果、患者の転帰が改善され、管理不十分な呼吸器疾患に関連する医療費が削減されます。

技術的進歩と接続性はどのようにスマート吸入器技術市場の成長を促進するか？

小型化と無線通信の革新により、スマート吸入器はよりコンパクトで使いやすく、アクセスしやすくなっています。バッテリー寿命の向上とBluetoothを介したスマートフォンとの統合は、ユーザーエクスペリエンスとデータ共有を向上させています。医療機器とアプリが連携するコネクテッドヘルスケアのエコシステムが拡大することで、スマート吸入器にとって理想的な環境が育まれています。この統合により、患者の健康状態をより総合的に把握し、ケア連携を改善することができます。喘息、COPD、嚢胞性線維症のような疾患の有病率の増加は、スマート吸入器採用の主要な推進力です。WHOによると、喘息は世界で約2億3,500万人が罹患しており、COPDは2030年までに死因の第3位になると予測されています。患者数の拡大に伴い、疾病管理を強化し、患者の転帰を改善するために、スマート吸入器のような革新的技術の必要性が高まっています。

スマート吸入器の高コストがスマート吸入器技術市場の成長をどのように抑制するか？

ヘルスケアコストの上昇は、政府や機関にスマート吸入器のような費用対効果の高いソリューションの採用を促しています。これらのデバイスは服薬アドヒアランスを高め、合併症を減らし、長期的な節約につながります。政府や民間保険会社は、医療提供者にスマート吸入器の統合を奨励し、市場成長を加速させています。特に先進国でヘルスケア支出が増加するにつれ、スマート吸入器のような先進ヘルスケア技術への投資が増加しています。増悪や入院を減らし、薬剤使用を最適化することで、スマート吸入器はケアの質、患者満足度、コスト効率を高める魅力的なソリューションを記載しています。標準的な吸入器と比較して、スマート吸入器には先進的センサ、ワイヤレス接続、モバイルアプリとの統合が組み込まれており、高価格につながります。このコストは一部の患者のアクセスを制限し、市場に広く受け入れられるための障壁となります。

スマート吸入器は、服薬アドヒアランスの向上や合併症の減少を通じて長期的なヘルスケアコストを削減することができるが、現在の償還制度では初期費用をカバーできないことが多いです。このような政府や保険会社からの財政的支援の欠如は、患者やヘルスケアプロバイダがこの技術を採用することを躊躇させる可能性があります。スマート吸入器は、薬の使用状況、吸入技術、潜在的な位置情報などの機密データを収集します。強固なデータプライバシーとセキュリティ対策を確保することは、ユーザーの信頼を維持し、データ漏洩を防ぐために不可欠です。企業はプライバシーの懸念に対処するため、強力なセキュリティプロトコルに投資し、データの取り扱い方法を伝えなければならないです。スマート吸入器の有効性は、ユーザーの受容と一貫した使用にかかっています。患者の中には、技術に抵抗があったり、追加の手続きを面倒に感じたりする者もいます。普及を促進するためには、ユーザーフレンドリーなインターフェースを設計し、その利点について患者を教育し、使い勝手の問題に対処することが極めて重要です。

目次

第1章 世界のスマート吸入器技術市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のスマート吸入器技術市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 スマート吸入器技術の世界市場：製品タイプ別

• 概要
• 乾燥粉末吸入器
• 定量吸入器

第6章 スマート吸入器技術の世界市場：適応症別

• 概要
• 喘息
• COPD（慢性閉塞性肺疾患）

第7章 スマート吸入技術の世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局

第8章 スマート吸入器技術の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のスマート吸入器技術市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Adherium
• Propeller Health
• Cohero Health Inc.
• GlaxoSmithKline
• AstraZeneca plc
• Novartis AG
• 3M Company
• Teva Pharmaceuticals
• Vectura Group
• Cognita Labs, Llc

第11章 付録

• 関連調査

Smart Inhaler Technology Market Valuation - 2026-2032

The increasing number of elderly individuals, who experience a higher prevalence of COPD and asthma, drives the demand for smart inhalers. Older adults are more prone to severe respiratory conditions and complications, making advanced inhaler technologies more essential. Thus, the increasing geriatric population surges the growth of market size surpassing USD 13.81 Billion in 2024 to reach a valuation of USD 57.7 Billion by 2032.

The rise in COVID-19 cases and its associated respiratory complications have heightened the need for effective respiratory management tools. Smart inhalers offer enhanced monitoring and adherence features, which are critical for managing respiratory disorders and reducing hospitalization risks. Thus, the rise in the COVID-19 pandemic and growth in effective respiratory management tools enable the market to grow at a CAGR of 19.6% from 2026 to 2032.

Smart Inhaler Technology Market: Definition/ Overview

The smart inhaler technology involves the integration of digital sensors and connectivity features into traditional inhaler devices used for managing respiratory conditions such as asthma and COPD. These advanced inhalers track medication usage, providing critical data to both patients and healthcare providers. Equipped with sensors that monitor doses, smart inhalers transmit data wirelessly to mobile apps or cloud platforms, where it is analyzed and displayed.

For patients, smart inhalers offer real-time feedback, helping them adhere to medication schedules, improve inhaler techniques, and receive reminders for timely usage. This can lead to better disease management, fewer asthma attacks or COPD exacerbations, and enhanced quality of life.

Healthcare providers benefit from the data generated by smart inhalers, which allows them to remotely monitor medication adherence, identify usage patterns, and adjust treatment plans. This data-driven approach enables personalized and proactive care, resulting in improved patient outcomes and reduced healthcare costs associated with poorly managed respiratory diseases.

How the Technological Advancements and Connectivity Foster the Growth of Smart Inhalers Technology Market?

Innovations in miniaturization and wireless communication are making smart inhalers more compact, user-friendly, and accessible. Enhanced battery life and integration with smartphones via Bluetooth improve user experience and data sharing. The growing connected healthcare ecosystem, where medical devices and apps work together, fosters an ideal environment for smart inhalers. This integration allows for a more holistic understanding of patient health and improved care coordination. The increasing prevalence of conditions like asthma, COPD, and cystic fibrosis is a key driver for smart inhaler adoption. According to WHO, asthma affects around 235 million people globally, and COPD is projected to become the third leading cause of death by 2030. As the patient population expands, there is a growing need for innovative technologies, such as smart inhalers, to enhance disease management and improve patient outcomes.

How does the High Cost of the Smart Inhalers Constraint the Growth of the Smart Inhalers Technology Market?

Rising healthcare costs are pushing governments and institutions to adopt cost-effective solutions like smart inhalers. These devices boost medication adherence and reduce complications, leading to long-term savings. Governments and private insurers incentivize healthcare providers to integrate smart inhalers, accelerating market growth. As healthcare spending rises, particularly in developed nations, investment in advanced healthcare technologies like smart inhalers is increasing. By reducing exacerbations, hospitalizations, and optimizing drug usage, smart inhalers offer a compelling solution to enhance care quality, patient satisfaction, and cost efficiency. Compared to the standard inhalers, the smart inhalers incorporate advanced sensors, wireless connectivity, and integration with mobile apps, leading to a higher price point. This cost limit access for some patients and act as a barrier to widespread market acceptance.

Although smart inhalers can reduce long-term healthcare costs through improved medication adherence and fewer complications, current reimbursement systems often do not cover their initial expense. This lack of financial support from governments and insurers can deter patients and healthcare providers from adopting the technology. Smart inhalers gather sensitive data, including medication usage, inhalation technique, and potential location information. Ensuring robust data privacy and security measures is essential to maintain user trust and prevent data breaches. Companies must invest in strong security protocols and communicate data handling practices to address privacy concerns. The effectiveness of smart inhalers relies on user acceptance and consistent use. Some patients are uncomfortable with technology or find the additional procedures cumbersome. To enhance adoption, it is crucial to design user-friendly interfaces, educate patients about the benefits, and address any usability issues.

Category-Wise Acumens

How is the DPI a Preferred Alternative for other Inhalers and Environmental Concern Surge the Growth of Dry Powdered Inhalers (DPI) Segment?

The dry powdered inhalers (DPI) segment dominates in the smart inhalers technology market owing to increasing concerns over the environmental impact of inhalers using chlorofluorocarbons (CFCs) as propellants. The DPIs have become a preferred alternative over pressurized Metered-Dose Inhalers (MDIs) and nebulizers for treating respiratory conditions like asthma and COPD. DPIs eliminate the need for harmful propellants, aligning with the growing emphasis on eco-friendly healthcare solutions.

Additionally, the rising demand for DPI-based inhalers is encouraging market players to develop more advanced and effective products. Smart DPIs are designed to deliver specific dry powder medications directly to the lungs, using a dry powder fluidization mechanism. These devices are integrated with features such as real-time feedback and data loggers that monitor and provide guidance on proper inhalation techniques, enhancing patient adherence and treatment effectiveness.

Moreover, collaboration between digital health and pharmaceutical companies is accelerating the development of innovative smart DPIs. This includes the integration of add-on sensors and advanced mechanisms for improved functionality, driving further growth in the segment. As technological advancements continue, DPI-based smart inhalers are expected to play a critical role in the future of respiratory disease management.

How Does the Increasing Prevalence of COPD Foster the Growth of COPD Segment?

The COPD segment is set to dominate the smart inhaler technology market, driven by the increasing prevalence of COPD worldwide. Several factors contribute to the growing number of COPD patients, including an aging population, continued exposure to risk factors like tobacco smoke and air pollution, and advancements in disease diagnosis. COPD is a significant health concern, accounting for 3.6% of the total disease burden and 50% of the respiratory disease burden globally in 2023.

The financial impact of COPD is substantial, with an estimated USD 831.6 Million spent on its treatment and management in 2020-21. This represents 0.6% of total healthcare expenditure and 18% of costs associated with all respiratory conditions. As the number of COPD patients rises, the demand for advanced management tools, such as smart inhalers, continues to grow.

In 2022, COPD was the underlying cause of 7,691 deaths, or 29.6 per 100,000 population, accounting for 4% of all deaths. The increasing prevalence and significant healthcare burden associated with COPD highlight the need for smart inhalers, which offer real-time monitoring, enhanced adherence, and improved disease management, making them essential tools in managing this chronic condition.

Country/Region-wise Acumens

How the Increasing Investment in Digital Health Technologies and Growing Prevalence of COPD Surge the Growth of Smart Inhalers Technology Market in North America?

North America is poised to dominate the smart inhaler technology market driven by its robust healthcare infrastructure, substantial investment in digital health technologies, and a rising prevalence of respiratory diseases like asthma and COPD. The increasing prevalence of asthma and COPD in the region fuels the growth of smart inhalers. For instance, 25 million people in the United States are affected by asthma, while more than 16 million individuals in the country suffer from chronic obstructive pulmonary disease (COPD).

The region's increasing awareness of the benefits of smart inhalers, including improved medication adherence, real-time monitoring, and personalized treatment, is further accelerating market growth. Patients and healthcare providers alike are recognizing the advantages of integrating smart inhalers into treatment plans, leading to higher adoption rates. Educational initiatives and marketing campaigns continue to raise awareness, emphasizing the practical benefits of these devices in managing respiratory conditions. The U.S. benefits from its advanced healthcare system, extensive research and development efforts, and a supportive regulatory landscape, positioning it as a leader in innovation and driving the growth of smart inhaler technology.

How does the Increasing Healthcare Expenditure Foster the Growth of the Smart Inhalers Technology Market in Asia Pacific?

The Asia-Pacific region is poised to emerge as the fastest-growing region in the smart inhaler technology market, driven by rising healthcare expenditures and a growing demand for advanced medical solutions. The healthcare budgets expand across the region, countries are increasingly directing resources toward innovative technologies aimed at improving patient outcomes and streamlining disease management. This surge in investment in healthcare infrastructure and technology adoption creates an ideal environment for the widespread introduction of smart inhalers.

In addition, the Asia-Pacific market is seeing a significant rise in product development and innovation as local and international manufacturers focus on addressing the region's specific needs. Companies are prioritizing research and development to create cost-effective, user-friendly smart inhalers tailored to the unique healthcare challenges and economic conditions of each country in the region. This surge in product innovation is expected to accelerate the adoption of smart inhalers, further solidifying the Asia-Pacific region as a major contributor to global market growth. With increasing healthcare demands and a focus on improving respiratory care, Asia-Pacific is anticipated to play a leading role in driving the expansion of smart inhaler technology during the forecast period.

Competitive Landscape

The competitive landscape of the Smart Inhaler Technology Market is dynamic and evolving. Established pharmaceutical companies and innovative technology startups are vying for market share by offering advanced solutions that improve patient outcomes and address the growing burden of respiratory diseases.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the smart inhaler technology market include:

• Adherium
• Propeller Health
• AstraZeneca
• Boehringer Ingelheim International GmbH
• GSK Group of Companies
• Cohero Health, Inc.
• AstraZeneca plc
• Novartis AG
• 3M Company,
• Teva Pharmaceuticals
• Vectura Group
• Cognita Labs, LLC.

Latest Developments:

• In August 2020, Propeller Health announced the partnership with Novartis to connect the Propeller digital health platform to Enerzair(R) and Atectura(R) Breezhaler, which are used to treat uncontrolled asthma, and to launch product distribution in Japan.
• In June 2020, Aptar Pharma announced the collaboration with Lupin Limited to produce ADHERO, India's first connected device for metered-dose nebulizers (MDI).

Smart Inhaler Technology Market, By Category

• Product Type:
• Dry Powdered Inhalers
• Metered Dose Inhalers
• Indication:
• Asthma
• COPD
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SMART INHALER TECHNOLOGY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SMART INHALER TECHNOLOGY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SMART INHALER TECHNOLOGY MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Dry Powdered Inhalers
• 5.3 Metered Dose Inhalers

6 GLOBAL SMART INHALER TECHNOLOGY MARKET, BY INDICATION

• 6.1 Overview
• 6.2 Asthma
• 6.3 COPD

7 GLOBAL SMART INHALER TECHNOLOGY MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospitals Pharmacies
• 7.3 Retail Pharmacies

8 GLOBAL SMART INHALER TECHNOLOGY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL SMART INHALER TECHNOLOGY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Adherium
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Propeller Health
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Cohero Health Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 AstraZeneca plc
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Novartis AG
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 3M Company
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Teva Pharmaceuticals
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Vectura Group
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Cognita Labs, Llc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research